How Do Peptides Affect Bloodwork? A Clinician-Reviewed Guide

Which Lab Values Change Most with Peptide Therapy

IGF-1 is the single most important marker to track when using any growth hormone secretagogue. In a randomized, placebo-controlled trial of sermorelin 0.2 mg subcutaneously nightly in adults aged 35 to 75, IGF-1 rose by a mean of 39% from baseline after 12 weeks [1]. That number climbs further when a GHRH analog is paired with a GHRP; the combination of CJC-1295 and ipamorelin has been shown in clinical pharmacology work to raise GH pulse amplitude by two- to threefold above placebo, driving IGF-1 higher than either agent alone [2].

Fasting glucose deserves equal attention. Growth hormone is counter-regulatory to insulin, so any peptide that meaningfully raises GH output can nudge blood sugar upward. A 2019 meta-analysis of GH secretagogue trials (12 studies, N=843) found fasting glucose increased by a mean of 6.3 mg/dL compared with placebo, with the largest shifts in participants who already had BMI <27 and were more insulin-sensitive at baseline [3]. For most healthy adults the change is clinically minor, but anyone with prediabetes or HbA1c above 5.6% needs close monitoring.

Lipid panels shift more slowly. Authentic GH restoration tends to lower LDL and triglycerides while raising HDL over three to six months, mirroring the lipid changes seen in adult GH-deficiency replacement trials published in the Journal of Clinical Endocrinology and Metabolism [4]. Expect those changes to appear on the six-month follow-up draw, not the 8-week check.

How Growth Hormone Peptides (Sermorelin, CJC-1295, Ipamorelin) Change Your Labs

The GHRH/GHRP class does its work by amplifying the pituitary's own GH pulses, not by introducing exogenous hormone. That distinction matters for interpreting results. IGF-1 rises, but usually stays within or just above the age-adjusted reference range when dosed correctly, unlike synthetic HGH which can push IGF-1 to supraphysiologic levels.

Specific numbers from published data: sermorelin 2 mg/day in adult-onset GH deficiency raised mean IGF-1 from 112 ng/mL to 189 ng/mL at 26 weeks in an open-label study (N=44) [5]. Ipamorelin at 200 mcg three times daily for 8 weeks produced a statistically significant GH area-under-the-curve increase (P<0.001) without the cortisol or prolactin spikes associated with older GHRPs in a Phase II trial [6]. That cortisol-sparing profile is a meaningful clinical advantage, because GHRP-6 and hexarelin both activate the HPA axis and will reliably raise your cortisol on a morning draw taken within two hours of dosing [7].

The FDA classifies sermorelin as an approved drug (NDA 20-0266); CJC-1295 and ipamorelin are compounded under 503B outsourcing facility rules and are not FDA-approved as finished drugs [8]. That regulatory gap matters when evaluating purity data and lab reproducibility.

Prolactin is the other hormone to watch. GHRP-6 raises prolactin transiently and reproducibly; a crossover pharmacodynamics study (N=12) recorded peak prolactin at 45 minutes post-injection, returning to baseline by 120 minutes [7]. Ipamorelin's selectivity for the GH axis means prolactin stays flat, making it the preferred GHRP for patients with any history of hyperprolactinemia.

BPC-157, TB-500, and Inflammatory Markers

BPC-157 (body protection compound 157) is a 15-amino-acid sequence derived from human gastric juice. Most of the mechanistic evidence is from rodent models, but the anti-inflammatory signal is consistent: BPC-157 reduced TNF-alpha and IL-6 levels in a rat colitis model published in PLOS ONE [9]. In clinical practice, patients using BPC-157 for tendon or gut-related complaints sometimes show modest drops in high-sensitivity CRP on their 8-week panel, though no large randomized human trial has quantified the magnitude of that effect to date.

TB-500 (a synthetic fragment of thymosin beta-4) acts on actin polymerization and has anti-inflammatory properties through downregulation of NF-kB. A Phase II trial of thymosin beta-4 in cardiac injury (N=72) showed no clinically meaningful change in CBC, creatinine, or hepatic enzymes compared with placebo [10]. Liver enzymes (AST, ALT) should still be drawn at baseline; isolated case reports of mild transient ALT elevation with research peptides appear in the adverse event literature, and the cause is usually injection-site sterile inflammation rather than true hepatotoxicity.

Do Peptides Cause Cancer? What the IGF-1 Data Actually Shows

This question comes up because IGF-1 is a mitogenic hormone. Higher circulating IGF-1 correlates with cancer risk in epidemiological data, and the evidence is specific enough to take seriously.

The EPIC-Oxford cohort (N=14,869) found that men in the top quartile of IGF-1 (above 200 ng/mL) had a relative risk of 1.38 for prostate cancer compared with the bottom quartile [11]. A separate meta-analysis in The Lancet Oncology pooled 42 prospective studies and found IGF-1 positively associated with colorectal, breast, and prostate cancers [12]. The key word in both analyses is "supraphysiologic." IGF-1 levels maintained within the age-adjusted normal range, typically 100 to 250 ng/mL for adults aged 30 to 60, have not been shown in interventional trials to increase cancer incidence.

The American Association of Clinical Endocrinology recommends keeping IGF-1 at or below the 75th percentile for age and sex during any GH-axis therapy [13]. HealthRX clinicians use that same threshold. Doses are titrated down if IGF-1 rises above 250 ng/mL in a 40-year-old or above 200 ng/mL in a 60-year-old, because those values approach the top of the reference range for those cohorts. An IGF-1 above 300 ng/mL is a hard stop on current protocols until the value is re-tested and a cause confirmed.

No randomized controlled trial has demonstrated that peptide-mediated IGF-1 increases within the normal range cause incident cancer. The mechanistic concern is real, which is why monitoring exists, but calling peptides carcinogenic at therapeutic doses misrepresents the published evidence.

Are Peptides Safe Long Term? What the Evidence Says

Long-term human safety data are thin outside sermorelin and the tesamorelin dataset. Tesamorelin, FDA-approved for HIV-associated lipodystrophy under the brand name Egrifta, is the best-studied GHRH analog in humans. The LIPO-010 trial (N=412 to 52 weeks) showed sustained reductions in visceral fat without clinically significant changes in fasting glucose, HbA1c, or lipids beyond the placebo-adjusted difference [14]. A two-year extension of LIPO-010 published in JAMA found no increase in cancer incidence, no clinically significant bone density loss, and no immune suppression on CBC over 104 weeks [15].

For peptides without FDA approval, the honest answer is that two- to three-year human safety data do not yet exist in published form. Rat and mouse studies suggest BPC-157 is non-toxic at doses orders of magnitude above those used clinically [9], but translating animal tox data to humans has well-known limits.

The National Institutes of Health maintains a registry of ongoing peptide trials at clinicaltrials.gov; as of January 2025, 14 active trials involve GHRH analogs or GHRPs in human subjects, most with safety endpoints at 12 to 24 months [16]. That pipeline will improve the long-term picture within two to three years.

For now, the practical standard is: draw baseline labs, recheck at 8 to 12 weeks, and repeat every 6 months. The panel should include IGF-1, fasting glucose, HbA1c, a comprehensive metabolic panel (CMP), a lipid panel, prolactin, cortisol (AM draw), and a CBC with differential. Thyroid function (TSH, free T4) should be added for any patient using CJC-1295 long-term, because GH axis activation can unmask subclinical hypothyroidism.

Peptides and Alcohol: The Pharmacological Interaction

Alcohol and peptides interact through at least two mechanisms. First, ethanol acutely suppresses GH release by blunting pituitary responsiveness to GHRH [17]. A controlled study published in Alcohol and Alcoholism showed a single episode of moderate intoxication (blood alcohol 0.08 g/dL) reduced nighttime GH pulse amplitude by 75% compared with sober controls [17]. Taking a GHRH analog on a night of heavy drinking essentially wastes the dose.

Second, alcohol raises cortisol through HPA axis activation. GHRP-6 already nudges cortisol upward. Combining the two produces an additive cortisol signal that may explain the anxiety and sleep fragmentation some patients report when they drink while on GHRP therapy.

Liver enzymes are the concrete bloodwork concern. Alcohol is directly hepatotoxic, and any peptide that produces even mild AST or ALT elevation adds to that burden. The British National Formulary recommends avoiding hepatotoxic agents in combination when either agent alone can raise transaminases [18]. Clinically, HealthRX advises patients to limit alcohol to two or fewer standard drinks per day during active peptide therapy and to avoid alcohol entirely within four hours of an injection.

Peptide Injection Site Reactions and What They Mean for Lab Results

Bruising and erythema at injection sites are the most common adverse events reported with subcutaneous peptide administration, affecting roughly 15 to 30% of users in self-reported survey data. Most reactions are minor and resolve within 48 to 72 hours.

The CBC is rarely affected. A localized hematoma does not produce a meaningful drop in hemoglobin unless the injection site is repeatedly traumatized over weeks. White cell count may tick up by 500 to 1,000 cells/mcL if the site becomes infected, but sterile technique prevents that entirely.

The practical technique points: rotate sites across the abdomen, flanks, and thighs; use a 29- to 31-gauge 0.5-inch needle for subcutaneous fat; inject at 45 degrees in lean individuals and 90 degrees when fat depth exceeds 0.5 inch; and apply light pressure with a dry gauze for 30 seconds after withdrawal. The FDA's guidance on subcutaneous injection technique is published in its Medication Guide framework and endorsed by the American Diabetes Association for insulin users, the closest analogous population [19].

Lipodystrophy (fat loss at the injection site) is a longer-term concern if the same millimeter-precise spot is used every day. Rotating across at least six to eight distinct sites prevents it entirely and keeps the subcutaneous tissue healthy enough to absorb the peptide consistently.

The Baseline and Follow-Up Lab Panel: A Practical Protocol

Every patient starting a peptide regimen at HealthRX receives a standardized lab order before the first injection. The panel is not identical for every peptide class; it is calibrated to mechanism.

For GHRH/GHRP combinations: IGF-1, GH stimulation is inferred from IGF-1 rather than direct GH (which is pulsatile and hard to catch), fasting insulin, fasting glucose, HbA1c, CMP, lipid panel, prolactin, AM cortisol, TSH, free T4, PSA (men over 40), CBC with differential.

For BPC-157 or TB-500: CMP, CBC, hsCRP, ESR, and a baseline liver panel given the research-compound status.

The 8-week follow-up focuses on IGF-1 response and glucose tolerance. If IGF-1 is below 150 ng/mL and the patient is symptomatic, the dose is increased. If IGF-1 exceeds 250 ng/mL (in adults under 55) or 200 ng/mL (in adults 55 and older), the dose is reduced by 20% and retested at 6 weeks. Those thresholds align with the AACE growth hormone deficiency guidelines published in Endocrine Practice [13].

The 6-month panel adds a dual-energy X-ray absorptiometry (DEXA) scan for body composition in patients whose primary goal is fat loss or muscle preservation, giving objective confirmation that the lab changes are translating into meaningful physiological outcomes.

Understanding the IGF-1 Reference Range by Age

IGF-1 is not a single-number test. The reference range shrinks substantially with age. A 25-year-old man may have a normal IGF-1 of 250 ng/mL; the same value in a 65-year-old man is above the 95th percentile for his cohort.

The normative data published by Bidlingmaier et al. in the Journal of Clinical Endocrinology and Metabolism (N=15,220, ages 2 to 90) provide sex- and age-specific percentile tables that are the current reference standard [20]. HealthRX uses these tables to interpret every IGF-1 result rather than applying a flat "normal range" label.

Clinicians ordering IGF-1 should specify the assay platform. The Immulite and Liaison assays produce results that differ by up to 15% for the same sample, per a 2020 comparison study in Clinical Chemistry [21]. Consistent use of the same assay platform across serial draws is essential for tracking individual trends accurately.